Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cytokinetics focuses on aficamten development post-FDA action, eyes international growth

Cytokinetics is navigating challenges post-CRL for omecamtiv mecarbil while focusing on aficamten's development.
Financially, the company is balancing increased expenses with revenue growth and strategic investments in R&D.
Key milestones for 2023 include FDA meetings for omecamtiv mecarbil and data expectations for aficamten.
The company's emphasis on aficamten's differentiation and clinical progress signals a strategic shift in focus.

Cytokinetics shifts focus to cardiovascular pipeline, optimistic outlook ahead

Cytokinetics focusing on cardiovascular pipeline progress, redirecting resources.
Optimistic outlook for aficamten and other cardiovascular drug candidates.
Financially stable with cash reserves and strategic cost-saving measures.

Cytokinetics reports strong Q2 progress, eyes market expansion opportunities

Cytokinetics made significant strides in Q2 2023, advancing key studies and reducing operating spending to enhance financial stability.
Positive data and progress in cardiovascular therapies showcase the company's potential in treating HCM and positioning in the market.
While facing challenges in stock performance and data disclosures, Cytokinetics remains poised for growth with opportunities in novel therapies and market expansion.

Cytokinetics excels in Q3 with aficamten progress and commercial readiness

Cytokinetics demonstrated strong operational and financial performance in Q3 2023, with a focus on advancing the aficamten program and preparing for potential commercialization.
While facing challenges related to data interpretation complexities and real-world beta blocker usage, the company remains well-positioned with compelling clinical aspects of aficamten.
Opportunities lie in potential partnerships for capital access, broad market potential across regions, and upcoming data disclosures driving market differentiation.

Cytokinetics excels with positive aficamten trial results and strategic focus

Cytokinetics' Q4 2023 marked a significant milestone with positive aficamten trial results, strong financial standing, and strategic focus on regulatory advancements and market expansion.
The company's strengths lie in aficamten's efficacy, financial stability, and potential for differentiated labeling, while challenges include adoption transitions and data analysis complexities.
Opportunities abound in accelerating NDA submission, expanding patient reach, engaging with payors, and leveraging data insights for enhanced patient outcomes and market positioning.
Overall, Cytokinetics is poised for growth and impact in 2024, with a clear roadmap for success in advancing aficamten and maximizing its therapeutic potential in the HCM market.

Cytokinetics advances aficamten for HCM treatment amid financial strength

Cytokinetics is making significant strides in advancing aficamten for HCM treatment, supported by positive results and regulatory engagements.
The company's financial strength and strategic focus on commercial readiness position it well for future growth and market penetration.
Challenges lie in addressing unmet needs in pediatric HCM, enrollment completion for ongoing trials, and establishing treatment credibility.
Opportunities exist in expanding diagnosis potential, developing competitive treatment options, and enhancing regulatory alignment for global market access.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytokinetics' (CYTK) CEO Robert Blum on Q1 2021 Results - Earnings Call Transcript

Secondary Analysis from GALACTIC-HF  to be Presented in Late Breaking Clinical Trial Session at ACC.21

Cytokinetics Reports First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an open-label extension clinical study designed to assess the long-term safety and tolerability of CK-3773274 (CK-274) in patients with symptomatic obstructive HCM (oHCM). Eligible patients have completed participation in REDWOOD-HCM, the Phase 2 clinical trial of CK-274, a next-in-class cardiac myosin inhibitor discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM

Next Cohort to Enroll Patients on Background Therapy of Disopyramide Next Cohort to Enroll Patients on Background Therapy of Disopyramide

Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment

Astellas Pharma Inc

Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associated with muscle weakness. Astellas had extended the research pact initially set to expire on December 31 last year, through March of this year.

Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics

SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

Cytokinetics to Announce First Quarter Results on May 6, 2021

Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration

Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 3:00 PM ET.

Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical Society Spring 2021 Virtual Meeting, taking place online from April 5, 2021 to April 30, 2021.

Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting

Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Cytokinetics (CYTK) is Overbought: Is A Drop Coming?

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q4 2020 Results - Earnings Call Transcript

Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF

Cytokinetics Reports Fourth Quarter 2020 Financial Results

Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development

Cytokinetics Names Muna Bhanji to Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

Cytokinetics to Announce Fourth Quarter Results on February 25, 2021

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach

Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants

Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals

Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy (HCM). CK-274 is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM.

Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing

Cytokinetics Regains European Rights to Omecamtiv Mecarbil

Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS

Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND

Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left Ventricular Ejection Fraction Below 50% Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left Ventricular Ejection Fraction Below 50%

Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2

Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction

Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking place online from December 9 – December 11, 2020.

Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND

Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting

Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum

Insmed

Aurinia Pharmaceuticals

NeoGenomics

Turning Point Therapeutics

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

News for Cytokinetics Stock (CYTK)